The global pharmaceutical dissolution testing services market was valued at USD 635.7 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.0% from 2023 to 2030. A rise in pharmaceutical research efforts is predicted to be the main factor driving the growth of the industry. Due to increased R&D expenditure by pharmaceutical companies as well as an increase in the number of novel medications entering the preclinical stage of development, there has also been an increase in demand for pharmaceutical dissolution testing services. The dissolution testing services were initially disturbed due to the pandemic.
This created an increased workload and a reduction in the internal lab testing capacities of various pharmaceutical companies. However, to mitigate or prevent these challenges, various strategies, like rotational shifts, reducing manpower, and working from home were adopted by companies. By the second half of the pandemic, the research studies for drug development started for the prevention of COVID-19 led to a rise in demand for pharmaceutical dissolution testing services. Dissolution testing is an essential tool for assessing the effectiveness of oral solid dose forms.
Its importance is rising due to the fact that medicine must first be released from the product and dissolved in the gastrointestinal fluids before it can be absorbed into the blood vessels to be effective. In other words, how quickly and how much of a medicine is absorbed depends on how easily it dissolves from the dosage form. According to The Food and Drug Administration Dissolution Database, there are 1444 drug products (July 2022) in the database that are in oral solid dose form. The oral solid dose is relatively simple to administer and it is simple to differentiate one oral solid dose product from another.
Moreover, oral solid dose manufacturing approaches are well-developed. Each has a repeatable distribution of ingredients, as well as uniformity in dissolution and bioavailability, to verify that the drug product is safe and effective. The performance of key companies is highly influenced by the level of demand from end users. Due to intense market efforts, increasing awareness levels, improving accessibility, and government initiatives; consumers, these days, are more concerned about self-care, resulting in higher consumption of healthcare products. The consumption levels are anticipated to rise exponentially over the forecast period.
The in-vitro method segment dominated the global market in 2022 and accounted for the largest share of more than 57.75% of the overall revenue. The segment is projected to expand further at the fastest growth rate maintaining its leading industry position throughout the forecast period. Two key factors driving the segment growth include an increase in preclinical pipeline capacity and growing awareness about dissolution testing.
In addition, the market for in-vitro pharmaceutical dissolution testing is anticipated to rise as a result of the traditional rising costs of animal tests as well as their socio-ethical problems. Market expansion is predicted to be supported by significant developments in the in-vitro dissolution testing assays used to evaluate the security of medicines and the potential impacts of those drugs on cells and tissues. To accommodate the rising demand for these assays, businesses are increasing their product lines as the market for in-vitro pharmaceutical dissolution testing expands.
Based on dosage form, the global industry has been further categorized into capsules, tablets, and others. The others segment includes syrup, ointments, eye/ear/nasal drops, powders, and aerosols. The tablets dosage form segment dominated the global industry in 2022 and accounted for the maximum share of more than 64.80% of the overall revenue. The segment is also anticipated to register the fastest CAGR maintaining its leading industry position throughout the forecast period.
This rapid growth can be attributed to the fact that tablets are simple to produce in large quantities, have excellent physical and chemical stability, and can be adjusted for the amount of medicine supplied to the body. The capsules segment is anticipated to register the second-fastest CAGR during the forecast period. Capsules are solid dosage forms. Some of the major drivers of this segment are the stability, easy availability of storage conditions, and easy formulation & development of capsules.
Based on dissolution apparatus, the global industry has been further categorized into basket, paddle, and others. The others segment includes a reciprocating cylinder, flow-through cell, paddle-over disc, rotating cylinder, and reciprocating disc. The paddle segment dominated the industry and accounted for the largest revenue share of more than 70.00% in 2022. The paddle is fixed vertically to a motor with variable speed and controlled speed. The tablet or capsule is put into a flask with a circular bottom for dissolving, and the equipment is kept at a steady temperature. This is widely used for the oral solid dosage form.
It is easy to use, can change pH, and can be easily automated for a routine checkup. The basket dissolution apparatus segment is likely to register the second-fastest CAGR during the forecast period. New equipment is positioned at the revolving shaft's end when using the basket dissolution method. It is made of non-reactive mesh and has a cylindrical form to avoid any unintended chemical interactions that might change the outcome. The main driver for the wide-scale adoption of this method is it can change its pH during the test.
North America dominated the global industry in 2022 and accounted for the maximum share of more than 53.00% of the overall revenue. The high share of this segment can be attributed to the presence of major companies providing pharmaceutical dissolution testing services and rising investments in R&D by them for the development of novel therapeutics for chronic diseases.
In addition, the development of the healthcare system and a rise in the burden of disease have increased the demand for novel therapeutics and, in turn, the demand for laboratory dissolution testing. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period owing to the rising investments by companies from developed economies in enhancing regional healthcare. Furthermore, service providers are establishing new facilities and forming alliances to increase the reach of their offerings to various locations in the region.
Businesses are undertaking strategies like product launches, M&A agreements, regional expansions, and product launches to gain a competitive edge. For instance, in October 2022, Agilent Technologies, Inc. announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. With this investment, Agilent will be able to unify all of its dissolution-related operations under one roof, simplifying cross-business collaboration and advancing the goal of innovation for the next dissolution products and services. Some of the prominent players in the global pharmaceutical dissolution testing services market include:
Intertek Group Plc.
Agilent Technologies, Inc.
Thermofisher Scientific Inc.
Charles River Laboratories
Pace Analytical Life Sciences
Market size value in 2023
USD 685.6 million
Revenue forecast in 2030
USD 1.2 billion
CAGR of 8.0% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company share, competitive landscape, growth factors and trends
Method, dosage form, dissolution apparatus, and region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; South Korea; Australia; Mexico; Brazil; Argentina; South Africa; Saudi Arabia; UAE
Intertek Group Plc.; Avivia BV; Almac Group; Agilent Technologies, Inc.; Catalent, Inc.; Thermofisher Scientific Inc.; Cambrex Corp; Charles River Laboratories; Boston Analytical; Pace Analytical Life Sciences; SOTAX; AMRI; SGS SA
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional, and segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pharmaceutical dissolution testing services market based on method, dosage form, dissolution apparatus, and region:
Method Outlook (Revenue, USD Million, 2018 - 2030)
Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)
Dissolution Apparatus Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global pharmaceutical dissolution testing services market size was estimated at USD 635.7 million in 2022 and is expected to reach USD 685.6 million in 2023.
b. The global pharmaceutical dissolution testing services market is expected to grow at a compound annual growth rate of 8.0% from 2023 to 2030 to reach USD 1.2 billion by 2030.
b. North America dominated the pharmaceutical dissolution testing services market with a share of 53.4% in 2022. This is attributable to the rapid increase in the manufacturing of pharmaceuticals to meet the rising demand for efficient healthcare and specialized expertise offered by CDMOs in the region.
b. Some key players operating in the pharmaceutical dissolution testing services market include Avivia BV, Almac Group, Agilent Technologies, Inc., Catalent, Inc., Thermofisher Scientific Inc., Cambrex, Charles River laboratories, Boston Analytical, Pace Analytical Life Sciences, SOTAX, AMRI, and SGS SA.
b. Key factors that are driving the pharmaceutical dissolution testing services market growth include the Rising burden of chronic and infectious diseases and Increasing R&D activities.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."